Emicizumab - Chugai Pharmaceutical

Drug Profile

Emicizumab - Chugai Pharmaceutical

Alternative Names: ACE 910; Anti-factor IXa x anti-factor X humanized bispecific antibody; CH5534262; HEMLIBRA; RG 6013; RO 5534262

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche
  • Class Antihaemorrhagics; Bispecific antibodies; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Haemophilia A

Most Recent Events

  • 01 Sep 2017 Phase-III clinical trials in Haemophilia A (In adolescents, In children, In infants) in Japan (SC) (JapicCTI-173710)
  • 29 Aug 2017 Emicizumab receives priority review status for haemophilia A (Prevention) in Australia
  • 25 Aug 2017 Emicizumab - Chugai Pharmaceutical receives Orphan Drug status for Haemophilia A (Prevention) in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top